Insmed Inc

Most Recent

  • uploads///Graph Part  Oct
    Company & Industry Overviews

    How are IBB’s Subgroups Performing?

    The iShares Nasdaq Biotechnology ETF (IBB) gives good exposure to various industries in the biotechnology industry. As of October 19, IBB rose by ~0.5%.

    By Peter Neil
  • Consumer

    Point72 Asset Management opens new position in Pier 1 Imports

    E-commerce represented approximately 1% of total sales in fiscal 2013, 4% in fiscal year 2014, 9% in the first quarter of fiscal 2015, and 9.7% in the second quarter of fiscal 2015.

    By Samantha Nielson
  • uploads///LL

    Point72 Asset Management raises stake in Lumber Liquidators

    The company “saw improvement in net sales trends over the course of the quarter as inventory levels recovered and the fall flooring season began.” But the shares are down 49% in the year to date.

    By Samantha Nielson
  • uploads///Cymabay

    Point72 Asset Management takes position in CymaBay Therapeutics

    CymaBay Therapeutics is a clinical-stage biopharmaceutical company formerly known as Metabolex. It develops therapies to treat metabolic and rare diseases with high unmet need.

    By Samantha Nielson
  • uploads///AGTC

    Point72 Asset Management adds position in Applied Genetic Tech

    Using the company’s partnerships and experience in ophthalmology, it plans to expand into a disease indication with a larger market. The company says it expects to place a new product candidate for this large market opportunity into development some time in 2015.

    By Samantha Nielson
  • uploads///INSM

    Point72 Asset Management raises position in Insmed

    “If approved for NTM patients, we believe Arikayce would be the first and only approved inhaled antibiotic for the treatment of NTM lung infections.” – Insmed

    By Samantha Nielson
  • uploads///Point
    Basic Materials

    Must-know positions traded by Point72 Asset Management

    Point72 focuses primarily on discretionary long and short equity investing and makes significant quantitative and macro investments. According to reports, the fund manages assets valued at between $9 billion and $10 billion.

    By Samantha Nielson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.